These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
1. ILMN exceeded Q2 earnings estimates with $1.19 EPS. 2. Sales reached $1.059 billion, surpassing forecasts. 3. CEO credits growth in consumables and clinical segment. 4. Adjusted EPS guidance for FY2025 raised to $4.45-$4.55. 5. Despite results, shares fell 6.8% post-announcement.